title: [Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
abstract: In France, women carrying BRCA1/2 mutation, at an identified high risk of breast cancer are recommended to undergo breast MRI screening. That screening does not however prevent the risk of developing a breast cancer. The only alternative to breast cancer screening available in France is surgical prevention by prophylactic mastectomy. An interesting option for women who wish to reduce their breast cancer risk, but are unready for prophylactic mastectomy is a preventive hormonal treatment by aromatase inhibitors, or selective estrogens receptor modulators (SERMs). Reliable clinical trials show the efficiency of tamoxifen, raloxifen, exemestane, and anastrozole especially, in reducing breast cancer incidence by 33%, 34%, 65% and 53% respectively. This article tries to sum up the main published trials of breast cancer prevention with hormonal treatment, and presents the latest American and English clinical guidelines concerning hormonal prevention for women at high risk of breast cancer, and starts thinking about the possibilities of hormonoprevention, especially among women carrying a BRCA1/2 mutation in France.
authors: Institut Curie, service de génétique, 26, rue d'Ulm, 75248 Paris cedex 5, France; Institut Bergonié, service de génétique - service de gynécologie, 229, cours de l'Argonne, 33000 Bordeaux, France. Electronic address: c.senechal-davin@bordeaux.unicancer.fr.
authors: Claire
authors: C
authors: Sénéchal
authors: Institut Curie, département de chirurgie, 75005 Paris, France.
authors: Fabien
authors: F
authors: Reyal
authors: Institut Curie, Saint-Cloud, service de génétique, 92210 Saint-Cloud, France.
authors: Nasrine
authors: N
authors: Callet
authors: Institut Curie, service de génétique, 26, rue d'Ulm, 75248 Paris cedex 5, France.
authors: Pascale
authors: P
authors: This
authors: Institut Curie, Saint-Cloud, service de génétique, 92210 Saint-Cloud, France.
authors: Catherine
authors: C
authors: Noguès
authors: Institut Curie, service de génétique, 26, rue d'Ulm, 75248 Paris cedex 5, France; Université Paris-Descartes, 75006 Paris, France.
authors: Dominique
authors: D
authors: Stoppa-Lyonnet
authors: Institut Curie, Saint-Cloud, service de génétique, 92210 Saint-Cloud, France.
authors: Emmanuelle
authors: E
authors: Fourme
mesh_terms: D000077384:Anastrozole; D000730:Androstadienes / Q000009:adverse effects / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000235:genetics* / Q000517:prevention & control*; D016889:Endometrial Neoplasms / Q000139:chemically induced; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D006801:Humans; D008408:Mastectomy; D009154:Mutation; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use; D065286:Prophylactic Surgical Procedures; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000730:Androstadienes; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D020849:Raloxifene Hydrochloride; C056516:exemestane
keywords: BRCA; Breast cancer prevention; Chemoprevention; Chimioprévention; Exemestane; High risk breast cancer; Hormonoprophylaxie; Hormonoprévention; Raloxifen; Raloxifène; Tamoxifen; Tamoxifène